Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cerevel Therapeutics Hldg Inc WT (CEREW)

Cerevel Therapeutics Hldg Inc WT (CEREW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -432,840 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CEREW with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 05/01/24 [--]
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.61
  • Number of Estimates 5
  • High Estimate -0.55
  • Low Estimate -0.70
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +8.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.00 +64.27%
on 08/20/21
20.07 -9.97%
on 08/27/21
+4.96 (+37.83%)
since 07/30/21
3-Month
3.87 +366.93%
on 06/28/21
20.07 -9.97%
on 08/27/21
+13.95 (+338.59%)
since 05/28/21
52-Week
1.50 +1,104.67%
on 10/20/20
20.07 -9.97%
on 08/27/21
+16.44 (+1,008.59%)
since 08/28/20

Most Recent Stories

More News
Cerevel Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain...

CEREW : 18.07 (-3.27%)
CERE : 41.90 (-0.21%)
Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-231 for the Treatment of Schizophrenia

Live webcast today from 10:00 to 11:30 a.m. ET CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company...

CERE : 41.90 (-0.21%)
CEREW : 18.07 (-3.27%)
Cerevel Therapeutics Announces Departure of CFO Kathy Yi

Current Chief Accounting Officer Mark Bodenrader named as interim CFO

CEREW : 18.07 (-3.27%)
CERE : 41.90 (-0.21%)
Cerevel Therapeutics to Host Virtual R&D Event on October 7

Event will focus on CVL-871, a D1/D5 partial agonist in development for dementia-related apathy, and will include an update on CVL-231, an M4 positive allosteric modulator for the treatment of schizophrenia...

CEREW : 18.07 (-3.27%)
CERE : 41.90 (-0.21%)
Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that...

CEREW : 18.07 (-3.27%)
CERE : 41.90 (-0.21%)
Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates

Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia

CEREW : 18.07 (-3.27%)
CERE : 41.90 (-0.21%)
Cerevel Therapeutics Announces Redemption of Public Warrants

CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE; CEREW) (the “Company”), a company dedicated to unraveling the mysteries of the brain to treat neuroscience...

CERE : 41.90 (-0.21%)
CEREW : 18.07 (-3.27%)
Cerevel Therapeutics to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...

CEREW : 18.07 (-3.27%)
CERE : 41.90 (-0.21%)
Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock

CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the...

CEREW : 18.07 (-3.27%)
CERE : 41.90 (-0.21%)
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that...

CEREW : 18.07 (-3.27%)
CERE : 41.90 (-0.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Cerevel Therapeutics Inc. treats neuroscience diseases. The company's diversified pipeline comprising clinical-stage investigational therapies and several preclinical compounds to treat neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics...

See More

Key Turning Points

3rd Resistance Point 18.07
2nd Resistance Point 18.07
1st Resistance Point 18.07
Last Price 18.07
1st Support Level 18.07
2nd Support Level 18.07
3rd Support Level 18.07

See More

52-Week High 20.07
Last Price 18.07
Fibonacci 61.8% 12.98
Fibonacci 50% 10.78
Fibonacci 38.2% 8.59
52-Week Low 1.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar